SecBot SecBot
8-K ·Filed Jun 23, 2026

PCVX

Vaxcyte, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago SEC0001649094-26-000026
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Monitor for any future material changes to the board or strategy. This filing is routine and does not warrant any trading action.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$53.87
T+0 close · Jun 23, 2026 · via day close
Latest settled
+12.07%
T+60 · $60.37
Vs SPY
+9.23%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 24 $53.87entry
  2. T+1 · 5mo ago −0.35%α −0.50% · $53.68
  3. T+5 · 5mo ago +4.10%α +2.40% · $56.08
  4. T+20 · 4mo ago +3.95%α +2.02% · $56.00
  5. T+60 · 2mo ago +12.07%α +9.23% · $60.37
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vaxcyte announced the retirement of board member Jacks Lee and the appointment of Moncef Slaoui as an independent Class II director, effective June 17, 2026. Dr. Slaoui will receive standard non-employee director compensation, including an annual equity grant currently valued at $430,000. This is a routine governance filing with no material financial or operational impact.

Key Facts

  • Director Jacks Lee retired effective June 17, 2026; will remain as a consultant on supply and manufacturing.
  • Moncef Slaoui appointed as an independent Class II director; term expires at the 2028 annual meeting.
  • Dr. Slaoui receives standard director compensation; annual equity grant is currently set at $430,000.

Financial Impact

No material financial impact. Dr. Slaoui's annual director equity grant is $430,000, which is immaterial relative to Vaxcyte's $7.5B market cap.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001649094-26-000026
Document: 0001649094-26-000026-index-headers.html0001649094-26-000026
Document: 0001649094-26-000026-index.html0001649094-26-000026
Document: 0001649094-26-000026.txt0001649094-26-000026

US Market Status

Market Closed · Opens Wed (12h 8m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 23, 2026